KLISBio is a clinical-stage regenerative medicine company. We are developing several innovative technology platforms based entirely on natural silk fibroin, which allow for the creation of various solutions for endogenous tissue repair and regeneration.
Silk is one of the most renowned and ancient materials used in medicine. In its raw state, silk consists of two main proteins, sericin and fibroin, with a glue-like layer of sericin coating two singular filaments of fibroin.
Silk fibroin is fully biocompatible and promotes cell proliferation by also stimulating in-vivo tissue regeneration. Depending on the technology used, it provides a unique combination of outstanding biological and mechanical properties.
KLISBio has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release, and a first-in-human study on nerve repair that is currently ongoing at the University of Zurich, Switzerland.
Silk is one of the most renowned and ancient materials used in medicine. In its raw state, silk consists of two main proteins, sericin and fibroin, with a glue-like layer of sericin coating two singular filaments of fibroin.
Silk fibroin is fully biocompatible and promotes cell proliferation by also stimulating in-vivo tissue regeneration. Depending on the technology used, it provides a unique combination of outstanding biological and mechanical properties.
KLISBio has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release, and a first-in-human study on nerve repair that is currently ongoing at the University of Zurich, Switzerland.
Location: Italy
Employees: 11-50
Total raised: $3.4M
Founded date: 2014
Investors 1
| Date | Name | Website |
| 19.12.2024 | Primo Vent... | primo.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.11.2021 | - | $3.4M | Principia ... |
Mentions in press and media 1
| Date | Title | Description |
| 18.03.2025 | Italy’s startup renaissance: closing in on Spain’s lead | At Tech.eu we are always keen to receive pitches from companies outside the big three — UK, France, and Germany. We've always regretted not receiving enough from Italian founders. But over the last few months, I'm hearing that Italy's start... |